You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 10,125,102


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,125,102 protect, and when does it expire?

Patent 10,125,102 protects ORLADEYO and is included in one NDA.

This patent has fifty-nine patent family members in twenty-eight countries.

Summary for Patent: 10,125,102
Title:Human plasma kallikrein inhibitors
Abstract: Disclosed are compounds of formula I ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Inventor(s): Kotian; Pravin L. (Birmingham, AL), Babu; Yarlagadda S. (Birmingham, AL), Wu; Minwan (Vestavia Hills, AL), Chintareddy; Venkat R. (Hoover, AL), Kumar; V. Satish (Birmingham, AL), Zhang; Weihe (Vestavia, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Durham, NC)
Application Number:15/123,059
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 10,125,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biocryst ORLADEYO berotralstat hydrochloride CAPSULE;ORAL 214094-001 Dec 3, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER ⤷  Try a Trial
Biocryst ORLADEYO berotralstat hydrochloride CAPSULE;ORAL 214094-002 Dec 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,125,102

PCT Information
PCT FiledMarch 09, 2015PCT Application Number:PCT/US2015/019535
PCT Publication Date:September 11, 2015PCT Publication Number: WO2015/134998

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.